1.05
price down icon3.67%   -0.04
after-market アフターアワーズ: 1.02 -0.03 -2.86%
loading
前日終値:
$1.09
開ける:
$1.07
24時間の取引高:
108.80K
Relative Volume:
0.67
時価総額:
$16.67M
収益:
$500.00K
当期純損益:
$-19.45M
株価収益率:
-0.5556
EPS:
-1.89
ネットキャッシュフロー:
$-18.22M
1週間 パフォーマンス:
-1.41%
1か月 パフォーマンス:
+17.88%
6か月 パフォーマンス:
-0.94%
1年 パフォーマンス:
-35.98%
1日の値動き範囲:
Value
$1.01
$1.07
1週間の範囲:
Value
$0.9705
$1.18
52週間の値動き範囲:
Value
$0.64
$3.65

Imunon Inc Stock (IMNN) Company Profile

Name
名前
Imunon Inc
Name
セクター
Healthcare (1164)
Name
電話
(609) 896-9100
Name
住所
997 LENOX DRIVE, LAWRENCEVILLE
Name
職員
0
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
IMNN's Discussions on Twitter

IMNN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
IMNN
Imunon Inc
1.05 16.67M 500.00K -19.45M -18.22M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Imunon Inc (IMNN) 最新ニュース

pulisher
06:12 AM

Companies To Watch: Imunon - Life Science Leader

06:12 AM
pulisher
Mar 28, 2025

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… - Zacks Small Cap Research

Mar 28, 2025
pulisher
Mar 28, 2025

Imunon (NASDAQ:IMNN) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 25, 2025

FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment - Yahoo

Mar 25, 2025
pulisher
Mar 25, 2025

Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

IMUNON advances to Phase 3 trial in ovarian cancer treatment By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Imunon finalizes Phase 3 study design with FDA for IMNN-001 - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

IMUNON advances to Phase 3 trial in ovarian cancer treatment - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Breakthrough Ovarian Cancer Treatment Shows 46-Month Survival as FDA Clears Phase 3 Trial - Stock Titan

Mar 24, 2025
pulisher
Mar 07, 2025

IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagionlive.com

Mar 07, 2025
pulisher
Mar 03, 2025

Imunon, Inc. Earnings Call: Clinical Success Amid Financial Challenges - TipRanks

Mar 03, 2025
pulisher
Mar 02, 2025

Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Imunon’s Strategic Clinical Advancements and Promising Research Drive Buy Rating - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Imunon, Inc. (NASDAQ:IMNN) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges - Yahoo Finance

Feb 28, 2025
pulisher
Feb 28, 2025

IMUNON, Inc. Reports 2024 Financial Results and Advances Clinical Programs - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Earnings call transcript: Imunon Q4 2024 reports improved EPS, stock declines - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

Imunon Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON Reports 2024 Financial Results and Provides Business Update - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON Reports 2024 Financial Results and Provides Business - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

IMUNON's Cancer Immunotherapy Shows 13-Month Survival Benefit in Ovarian Cancer | IMNN Stock News - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial - Yahoo Finance

Feb 27, 2025
pulisher
Feb 26, 2025

Imunon announces new analyses of results from Phase 1 trial of IMNN-101 - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

IMUNON Announces New Immunogenicity Data from Phase 1 - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can IMUNON's DNA Vaccine Outperform mRNA COVID Shots? New Clinical Data Reveals Key Advantages - StockTitan

Feb 26, 2025
pulisher
Feb 22, 2025

Imunon (IMNN) Expected to Announce Quarterly Earnings on Thursday - Defense World

Feb 22, 2025
pulisher
Feb 20, 2025

Imunon Inc [IMNN] Shares Jump Approximately 66.98% Over the Year - Knox Daily

Feb 20, 2025
pulisher
Feb 20, 2025

The time has not yet come to remove your chips from the table: Imunon Inc (IMNN) - SETE News

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON, Inc. to Announce Full Year 2024 Financial Results on February 27, 2025 - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

New Phase II data confirm promise of Imunon’s IMMN-001 - The Pharma Letter

Feb 20, 2025
pulisher
Feb 20, 2025

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire

Feb 20, 2025
pulisher
Feb 19, 2025

Imunon Announces Translational Data From Phase 1/2 Ovation 2 Study Of Imnn-001 In Advanced Ovarian Cancer - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Ovarian Cancer Breakthrough? New Drug Shows 13-Month Survival Advantage in Clinical Trial - StockTitan

Feb 19, 2025
pulisher
Feb 11, 2025

IMUNON names Douglas Faller as chief medical officer - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire

Feb 11, 2025
pulisher
Feb 10, 2025

Imunon names industry vet Douglas Faller as CMO - The Pharma Letter

Feb 10, 2025
pulisher
Feb 10, 2025

Imunon Appoints Dr. Douglas Faller as CMO - TipRanks

Feb 10, 2025
pulisher
Feb 10, 2025

Oncology Veteran Takes Helm at IMUNON as Phase 3 Trial ApproachesKey Details - Stock Titan

Feb 10, 2025
pulisher
Jan 30, 2025

Imunon director Donald Braun acquires $29,480 worth of shares - MSN

Jan 30, 2025
pulisher
Jan 26, 2025

Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World

Jan 26, 2025
pulisher
Jan 24, 2025

Biotech's Target Price 183.757% Higher Than Current - Streetwise Reports

Jan 24, 2025
pulisher
Jan 07, 2025

Is Rigetti Computing Stock a Buy in 2025? - The Globe and Mail

Jan 07, 2025
pulisher
Dec 19, 2024

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewswire

Dec 19, 2024
pulisher
Dec 19, 2024

IMUNON Secures FDA Alignment for Phase 3 Ovarian Cancer Immunotherapy Manufacturing Strategy - StockTitan

Dec 19, 2024

Imunon Inc (IMNN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):